Reliant Investment Management LLC bought a new position in Eli Lilly and Co (NYSE:LLY) in the 4th quarter, HoldingsChannel.com reports. The institutional investor bought 34,474 shares of the company’s stock, valued at approximately $2,912,000.

Several other institutional investors and hedge funds have also bought and sold shares of LLY. Janus Henderson Group PLC increased its stake in shares of Eli Lilly and by 7,093.5% in the second quarter. Janus Henderson Group PLC now owns 9,353,275 shares of the company’s stock worth $769,774,000 after purchasing an additional 9,223,251 shares in the last quarter. Dodge & Cox increased its stake in shares of Eli Lilly and by 22,094.9% in the second quarter. Dodge & Cox now owns 5,991,952 shares of the company’s stock worth $493,138,000 after purchasing an additional 5,964,955 shares in the last quarter. Renaissance Technologies LLC increased its stake in shares of Eli Lilly and by 91.1% in the second quarter. Renaissance Technologies LLC now owns 5,694,905 shares of the company’s stock worth $468,691,000 after purchasing an additional 2,714,505 shares in the last quarter. Bank of Montreal Can increased its stake in shares of Eli Lilly and by 85.4% in the fourth quarter. Bank of Montreal Can now owns 4,631,241 shares of the company’s stock worth $391,156,000 after purchasing an additional 2,133,606 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in shares of Eli Lilly and by 2.3% in the second quarter. Vanguard Group Inc. now owns 70,207,891 shares of the company’s stock worth $5,778,109,000 after purchasing an additional 1,610,885 shares in the last quarter. Hedge funds and other institutional investors own 76.45% of the company’s stock.

LLY has been the subject of several recent research reports. Jefferies Group set a $100.00 target price on shares of Eli Lilly and and gave the stock a “buy” rating in a research note on Tuesday, January 16th. Goldman Sachs Group downgraded shares of Eli Lilly and from a “buy” rating to a “neutral” rating and lifted their target price for the stock from $86.98 to $95.00 in a research note on Tuesday, January 16th. Argus upgraded shares of Eli Lilly and from a “hold” rating to a “buy” rating and raised their price objective for the company from $85.52 to $115.00 in a research report on Friday, January 5th. BMO Capital Markets set a $73.00 price objective on shares of Eli Lilly and and gave the company a “sell” rating in a research report on Tuesday, December 5th. Finally, Piper Jaffray Companies restated a “buy” rating and issued a $105.00 price objective on shares of Eli Lilly and in a research report on Friday, October 13th. Three equities research analysts have rated the stock with a sell rating, eight have assigned a hold rating and nine have given a buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus target price of $92.02.

In other Eli Lilly and news, SVP Susan Mahony sold 36,585 shares of Eli Lilly and stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $86.18, for a total transaction of $3,152,895.30. Following the completion of the sale, the senior vice president now directly owns 54,885 shares in the company, valued at $4,729,989.30. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, SVP Jeffrey N. Simmons sold 12,500 shares of Eli Lilly and stock in a transaction that occurred on Monday, December 11th. The shares were sold at an average price of $86.46, for a total transaction of $1,080,750.00. Following the sale, the senior vice president now owns 124,522 shares of the company’s stock, valued at $10,766,172.12. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 259,610 shares of company stock valued at $22,727,406. 0.20% of the stock is currently owned by company insiders.

Shares of Eli Lilly and Co (LLY) opened at $76.23 on Friday. Eli Lilly and Co has a 1 year low of $73.69 and a 1 year high of $89.09. The stock has a market cap of $81,712.27, a P/E ratio of -381.13, a price-to-earnings-growth ratio of 1.36 and a beta of 0.23. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.03 and a current ratio of 1.38.

Eli Lilly and (NYSE:LLY) last announced its earnings results on Wednesday, January 31st. The company reported $1.14 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.08 by $0.06. Eli Lilly and had a negative net margin of 0.89% and a positive return on equity of 31.44%. The business had revenue of $6.16 billion during the quarter, compared to analyst estimates of $5.93 billion. During the same period in the previous year, the business posted $0.95 earnings per share. Eli Lilly and’s revenue for the quarter was up 7.0% on a year-over-year basis. equities research analysts anticipate that Eli Lilly and Co will post 4.87 EPS for the current year.

The business also recently announced a quarterly dividend, which will be paid on Friday, March 9th. Shareholders of record on Thursday, February 15th will be given a dividend of $0.5625 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This is a positive change from Eli Lilly and’s previous quarterly dividend of $0.52. This represents a $2.25 annualized dividend and a yield of 2.95%. Eli Lilly and’s payout ratio is presently -1,039.95%.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another publication, it was stolen and republished in violation of US and international copyright legislation. The legal version of this article can be viewed at https://www.thecerbatgem.com/2018/02/10/reliant-investment-management-llc-takes-2-91-million-position-in-eli-lilly-and-co-lly.html.

Eli Lilly and Profile

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Co (NYSE:LLY).

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.